相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Upregulating Reverse Cholesterol Transport With Cholesteryl Ester Transfer Protein Inhibition Requires Combination With the LDL-Lowering Drug Berberine in Dyslipidemic Hamsters
Francois Briand et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2013)
Dalcetrapib, a cholesteryl ester transfer protein modulator
Amanda J. Hooper et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2012)
Effects of CETP inhibition on triglyceride-rich lipoprotein composition and apoB-48 metabolism
Margaret R. Diffenderfer et al.
JOURNAL OF LIPID RESEARCH (2012)
New molecular insights into CETP structure and function: a review
M. Arthur Charles et al.
JOURNAL OF LIPID RESEARCH (2012)
Genetic Inhibition of CETP, Ischemic Vascular Disease and Mortality, and Possible Adverse Effects
Trine Holm Johannsen et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2012)
Challenges in multi-plex and mono-plex platforms for the discovery of inflammatory profiles in neurodegenerative diseases
Arjan Malekzadeh et al.
METHODS (2012)
Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome
Gregory G. Schwartz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
CETP Inhibitor Torcetrapib Promotes Reverse Cholesterol Transport in Obese Insulin-Resistant CETP-ApoB100 Transgenic Mice
Francois Briand et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2011)
Effects of the CETP Inhibitor Evacetrapib Administered as Monotherapy or in Combination With Statins on HDL and LDL Cholesterol A Randomized Controlled Trial
Stephen J. Nicholls et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Inflammation and the Development of Atherosclerosis -Effects of Lipid-Lowering Therapy
Yoshiko Mizuno et al.
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS (2011)
Anacetrapib promotes reverse cholesterol transport and bulk cholesterol excretion in Syrian golden hamsters
Jose Castro-Perez et al.
JOURNAL OF LIPID RESEARCH (2011)
Biphenyl-Substituted Oxazolidinones as Cholesteryl Ester Transfer Protein Inhibitors: Modifications of the Oxazolidinone Ring Leading to the Discovery of Anacetrapib
Cameron J. Smith et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Biliary Sterol Secretion Is Not Required for Macrophage Reverse Cholesterol Transport
Ryan E. Temel et al.
CELL METABOLISM (2010)
Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial
Evan A. Stein et al.
EUROPEAN HEART JOURNAL (2010)
Biochemical characterization of cholesteryl ester transfer protein inhibitors
Mollie Ranalletta et al.
JOURNAL OF LIPID RESEARCH (2010)
Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport
Eric J. Niesor et al.
JOURNAL OF LIPID RESEARCH (2010)
Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients
Daniel Bloomfield et al.
AMERICAN HEART JOURNAL (2009)
Lessons Learned from the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) Trial
Philip Barter
AMERICAN JOURNAL OF CARDIOLOGY (2009)
Overexpression of Apolipoprotein F Reduces HDL Cholesterol Levels In Vivo
William R. Lagor et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2009)
Effects of nevirapine and efavirenz on HDL cholesterol levels and reverse cholesterol transport in mice
Junichiro Tohyama et al.
ATHEROSCLEROSIS (2009)
Polymorphism in the CETP Gene Region, HDL Cholesterol, and Risk of Future Myocardial Infarction Genomewide Analysis Among 18 245 Initially Healthy Women From the Women's Genome Health Study
Paul M. Ridker et al.
CIRCULATION-CARDIOVASCULAR GENETICS (2009)
Inhibition of CETP by torcetrapib attenuates the atherogenicity of postprandial TG-rich lipoproteins in type IIB hyperlipidemia
Maryse Guerin et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2008)
Multiple-Dose Pharmacodynamics and Pharmacokinetics of Anacetrapib, a Potent Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Healthy Subjects
R. Krishna et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk
Alexander Thompson et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2008)
Effects of torcetrapib in patients at high risk for coronary events
Philip J. Barter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in New Zealand White rabbits
Lee A. Morehouse et al.
JOURNAL OF LIPID RESEARCH (2007)
Cholesteryl ester transfer protein decreases high-density lipoprotein and severely aggravates atherosclerosis in APOE* 3-Leiden mice
Marit Westerterp et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2006)
Atheroprotective potential of macrophage-derived phospholipid transfer protein in low-density lipoprotein receptor-deficient mice is overcome by apolipoprotein AI overexpression
David T. Valenta et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2006)
Development of siRNA for therapeutics: Efficient synthesis of phosphorothioate RNA utilizing phenylacetyl disulfide (PADS)
VT Ravikumar et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2006)
Plasma cholesteryl ester transfer is a determinant of intima-media thickness in type 2 diabetic and nondiabetic subjects: Role of CETP and triglycerides
R de Vries et al.
DIABETES (2005)
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins
C Baigent et al.
LANCET (2005)
Determining hepatic triglyceride production in mice: comparison of poloxamer 407 with Triton WR-1339
JS Millar et al.
JOURNAL OF LIPID RESEARCH (2005)
Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion
ME Brousseau et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2005)
Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with Pravastatin in type II dyslipidemia
JA Kuivenhoven et al.
AMERICAN JOURNAL OF CARDIOLOGY (2005)
Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol
ME Brousseau et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines
SM Grundy et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2004)
Overexpression of apolipoprotein A-I promotes reverse transport of cholesterol from macrophages to feces in vivo
YZ Zhang et al.
CIRCULATION (2003)
Cholesteryl ester transfer protein inhibitor (JTT-705) and the development of atherosclerosis in rabbits with severe hypercholesterolaemia
ZP Huang et al.
CLINICAL SCIENCE (2002)
LRP: a multifunctional scavenger and signaling receptor
J Herz et al.
JOURNAL OF CLINICAL INVESTIGATION (2001)
分享论文
